Int J Curr Pharm Res, Vol 12, Issue 2, 104-107Original Article
DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRICMETHOD FOR QUANTITATIVE ESTIMATION OF GLIPIZIDEIN PHARMACEUTICAL DOSAGE FORM
ANUJA SURYAWANSHI1*, AFAQUEANSARI1, MALLINATH KALSHETTI1
1D. S. T. S. Mandal’S College of Pharmacy, Solapur 413004, Maharashtra, India
Email: anujasuryawanshi001@gmail.com
Received: 15 Nov 2019, Revised and Accepted: 19 Jan 2020
ABSTRACT
Objective: The present work is aimed to develop a simple, rapid, selective and economical UV spectrophotometric method for quantitative determination of Glipizideinbulk and pharmaceutical dosage form.
Methods: In this method Dimethyl Form amide (DMF) was used as solvent, the absorption maxima was found to be275 nm in DMF. The developed method was validated for linearity, accuracy, precision, ruggedness, robustness, LOD and LOQ in accordance with the requirements of ICH guideline.
Results: The linearity was found to be 10-60 µg/ml having linear equation y=0.017x-0.006 with correlation coefficient of 0.997. The% recovery was found to be in the range of 98.7-100%. The % RSD for intra-day and inter-day precision was found to be 0.569923 and 0.40169 respectively. The limit of detection (LOD) and limit of quantification (LOQ) was found to be3.06 µg/ml and 9.27 µg/ml respectively.
Conclusion: The developed method was validated as per ICH Q2(R1) guidelines. The novel method is applicable for the analysis of bulk drug in its pharmaceutical dosage form.
Keywords: Glipizide, UV-Spectrophotometric method, Method Development and validation, Dimethyl Form amide
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
DOI: http://dx.doi.org/10.22159/ijcpr.2020v12i2.37502. Journal homepage: https://innovareacademics.in/journals/index.php/ijcpr
INTRODUCTION
Glipizide(1-cyclohexyl-3-[[4-[2-[[(5-methylpyrazine-2-yl) carbonyl] amino] ethyl] phenyl] sulphonyl] urea),1is a second-generationsulfonyl urea derivative that is widely used as oral antihyperglycemic drug for the treatment non-insulin dependent diabetes mellitus [2-6].
Fig. 1: Structure of glipizide
The present study is aimed to develop a simple, rapid, selective and economical UV spectrometric method for quantitative determination of Glipizide in bulk and pharmaceutical dosage form. The method was demonstrated as per ICH Q2(R1) guidelines [7-11].
MATERIALS AND METHODS
Materials used
Pure standard Glipizide was obtained as a gift sample from Ajanta pharma Ltd. Mumbai. Commercial tablet of Glipizide formulation was purchased as research sample from Wockhardt Ltd, Aurangabad. DMF is used as a solvent.
Instrument used
UV-Visible double beam spectrophotometer (Systronics-2201) with 1 cm matches quartz cell, electronic balance (SHIMADZU-AY220) and asonicator (Oscar ultrasonic cleaner Microclean-103) was used in the study.
Fig. 2: Absorption maxima of glipizide at 275 nm
Preparation of standard stock solution
Standard stock solution of Glipizide (GLP) was prepared by dissolving 10 mg GLP in 10 ml of DMF to obtain concentration of 1000µg/ml.
Spectrum measurement of glipizide in DMF
The second stock solution was prepared by diluting 0.5 ml of the above standard stock solution upto10 ml and scanned between 200-400 nm in UV Visible double beam spectrophotometer. The UV absorption spectrum of Glipizide showed peak at 275 nm. The maximum wavelength of 275 nm was selected for the present study.
Assay
Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 10 mg of glipizide transferred into 10 ml of volumetric flask and dissolved in DMF. This solution was sonicated and the final volume was made up to the mark with DMF. 1 ml of solution was transferred into 10 ml volumetric flask and adjust upto the mark with DMF. The absorbance of this solution measured at 275 nm. The result of assay was shown in table 1.
Method validation
Validation parameter such as Linearity and range, Accuracy, precision, ruggedness, robustness, LOD and LOQ according to ICH Q2(R1) guideline [12].
Linearity
Aliquots of 0.1, 0.2, 0.3, 0.4,0.5 and 0.6 were taken from standard stock solution and the volume made upto10 ml with DMF. Calibration curve was plotted between absorbance versus concentration (fig. 3).
Table 1: Assay of glipizide tablet
| Brand name | Label claim | Assay |
| Glynase | 5 mg | 98.5 % |
Table 2: Linearity of glipizide
| S. No. | Concentration (µg/ml) | Absorbance |
| 1 | 10 | 0.144 |
| 2 | 20 | 0.344 |
| 3 | 30 | 0.523 |
| 4 | 40 | 0.693 |
| 5 | 50 | 0.846 |
| 6 | 60 | 1.007 |
| Regression equation y=0.0171x-0.0063 | ||
| R2=0.9977 |
Fig. 3: Calibration curve of glipizide in DMF
Range
The range of an analytical procedure is an interval between upper and lower concentration of an analyte in the sample for which it has been showed that the analytical procedure has a suitable level of linearity, accuracy, precision. The obtained range of an analyte is 10 to 60 µg/ml.
Accuracy
Accuracy was determined by preparing solution of different concentration that is 50%, 100%, 150%. The percentage recovery was calculated (table 3).
Precision
The precision (measurement of intra-day, inter-day) determined by analyzing the six samples of same concentration (30 µg/ml) the absorbance was noted. From the measured absorbance result mean, standard deviation and % RSD was calculated.
Ruggedness
Ruggedness of the method was determined by analyzing same sample by different analysts (analyst 1 and 2) at different condition and the respective absorbance were noted and result was indicated as %RSD.
Robustness
Robustness of the method was determined by carrying out the analysis at two different wavelength (275 and 277) preparing solution 15 µg/ml.
Limit of detection (LOD)
The limit of detection (LOD) was determined by using linearity.
LOD was calculated by using equation-
LOD= 3.3 δ/s
Where δ is a standard deviation and s is the slope.
Table 3: Result for accuracy
| Name of drug | Level of recovery | Concentration (µg/ml) | Amount recovery | Mean % recovery |
| Glipizide | 50% | 20 | 19.84 | 99.2 |
| 100% | 40 | 39.84 | 99.6 | |
| 150% | 60 | 59.25 | 98.75 |
Table 4: Intraday precision data of glipizide
| S. No. | Concentration (µg/ml) | Absorbance |
| 1. | 30 | 0.524 |
| 2. | 30 | 0.529 |
| 3. | 30 | 0.528 |
| 4. | 30 | 0.526 |
| 5. | 30 | 0.532 |
| 6. | 30 | 0.531 |
Mean SD |
0.528333 0.003011 0.569923 |
Table 5: Interday precision data of glipizide
| S. No. | Concentration (µg/ml) | Absorbance |
| 1 | 30 | 0.524 |
| 2 | 30 | 0.528 |
| 3 | 30 | 0.529 |
| 4 | 30 | 0.527 |
| 5 | 30 | 0.530 |
| 6 | 30 | 0.531 |
Mean SD %RSD |
0.528167 0.002483 0.40169 |
Table 7: Result of ruggedness
| S. No. | Concentration (µg/ml) | Absorbance (analyst 1) | Absorbance (analyst 2) |
| 1 | 30 | 0.524 | 0.522 |
| 2 | 30 | 0.520 | 0.518 |
| 3 | 30 | 0.519 | 0.521 |
| 4 | 30 | 0.521 | 0.522 |
| 5 | 30 | 0.518 | 0.520 |
| 6 | 30 | 0.522 | 0.525 |
Mean SD %RSD |
0.52066667 0.00216025 0.41490017 |
0.521333 0.002338 0.448483 |
Table 8: Robustness at wavelength 275 nm and 277 nm (conc.15 µg/ml)
| S. No. | Concentration. µg/ml | Absorbance (275) | Absorbance (277) |
| 1 | 15 | 0.253 | 0.252 |
| 2 | 15 | 0.255 | 0.254 |
| 3 | 15 | 0.254 | 0.256 |
| 4 | 15 | 0.254 | 0.255 |
| 5 | 15 | 0.251 | 0.253 |
| 6 | 15 | 0.254 | 0.256 |
Mean SD %RSD |
0.2535 0.0013784 0.54374940 |
0.2543333 0.00163299 0.64206808 |
Table 9: For limit of detection
| LOD | Concentration(µg/ml) |
| Glipizide | 3.06 |
Table 10: For limit of quantification
| LOQ | Concentration(µg/ml) |
| Glipizide | 9.27 |
Table 11: Optimization parameters of glipizide
| S. No. | Parameters | Glipizide |
| 1 | Beer’s Law Limit | 10-60 µg/ml |
| 2 | Absorption maxima (nm) | 275 nm |
| 3 | Standard regression equation | Y= 0.0171x-0.0063 |
| 4 | Correlation coefficient r2 | r2= 0.9977 |
| 5 | Assay | 98.5% |
| 6 | Accuracy | 98.75-100 % |
| 7 | Precision intra-day and inter-day(%RSD) | 0.569923 and 0.40169% |
| 8 | Ruggedness (%RSD) | 0.4149 and 0.4484 |
| 9 | Robustness (%RSD) | 0.5437 and 0.4484 |
| 10 | LOD | 3.06(µg/ml) |
| 11 | LOQ | 9.27(µg/ml) |
Limit of quantification (LOQ)
The limit of quantification is an individual analytical procedure is the lowest amount of analyte in the sample. LOQ was calculated byusing equation-
LOQ= 10 δ/s
Where δ is a standard deviation and s is the slope.
RESULTS AND DISCUSSION
The UV scan of standard stock solution 200-400 nm showed the absorption maxima at 275 nm. The overlay spectra of different concentration range of std Glipizide was recorded (fig. 2). Beers-Lambert’s law is applicable in the concentration range between 10 to 60 µg/ml. The regression equation was found to be Y=0.0171x-0.0063 and correlation coefficient was found to be 0.9977. The % assay of Glipizide tablet was found to be 98.5%. validation parameters are developed as per ICH guideline. Accuracy was found to be 98.75-100% recovery. Precision for intra-day and inter-day of %RSD was found to be 0.5746 and 0.4363. LOD and LOQ was found to be 3.06µg/ml and 9.27µg/ml by using the formula. Ruggedness was calculated by two different analysts and two different laboratories and the % RSD was found to be 0.4149 and 0.4484. Robustness was calculated by two different wavelength 275 and 277and the %RSD was found to be 0.5437 and 0.6420. Hence the proposed method was developed in validation parameters and the method were found to be simple, rapid, accurate and precise for the routine analysis of glipizide in bulk pharmaceutical dosage form.
CONCLUSION
A simple, rapid and precise UV-visible spectrophotometric method has been developed for the determination of glipizide in marked formulation. The developed method was validated for linearity, accuracy, precision (inter-day and intra-day), robustness, ruggedness, LOD and LOQ parameters studies. The result of all these parameters shows that the rapid, accurate, linear and precise. This method can be successfully applied for routine estimation of glipizide in bulk pharmaceutical dosage form.
ACKNOWLEDGEMENT
The authors are thankful to the Principal and management of D. S. T. S. Mandal’s College of Pharmacy, Solapur, Maharashtra for providing the research facility to carry out this work.
FUNDING
Nil
AUTHORS CONTRIBUTIONS
All the authors have contributed equally.
CONFLICT OF INTERESTS
Declare none
REFERENCES
Indian Pharmacopoeia. Ghaziabad: Indian pharmacopeia commission; 2007. p. 1167.
Karkhanis VV. Development and validation of UV spectrophotometric method for estimation of glipizide in bulk and pharmaceutical dosage forms. Int J Pharm Sci Res 2013;4:1865-7.
Chungath TT. Simultaneous spectrophotometric estimation of metformin hydrochloride and glipizide tablet. Int J PharmTech Res 2011;3:2064-7.
Rathod DR, Dole MN. Spectrophotometric determination of glipizide in bulk and tablet dosage form by absorption maxima, first order derivative spectroscopy and area under curve. Asian J Pharma Clin Res 2012;5:102-4.
Basavaiah KK, Rajendraprasad NH. Stability-indicating Uv-spectrophotometric determination of glipizide in pharmaceuticals. Austin J Anal Pharma Chem 2017;4:1-7.
Nipanikar MS, Baokar SS. Ultraviolet spectrophotometric method for determination of glipizide in bulk and tablet dosage formulation. Res J Pharm Dosage Form Tech 2016;11:234-9.
Patil GS. Development and validation of UV spectrophotometric method for simultaneous estimation of metformin and glipizide tablet formulation. Int J Appl Pharm Sci Res 2016;1:56-9.
Buddhadev SV, Kashyap RS. Development and validation of simultaneous equation method for bilayer floating tablet of glipizide and lisinopril. Int J Innovative Pharm Sci Res 2015:3:212-20.
Jena BR, Swain SS. UV spectrophotometric method developmentand quantitative estimation of glipizide in bulkand pharmaceutical dosage forms. Int J Drug Res Tech 2017;7:112-22.
Sarangi RR, Panda SN. Simultaneous UV-spectrophotometric estimation of glipizide and metformin in bulk and its dosage form. Int J Pharm Biol Arch 2011;2:1137-45.
https://www.drugbank.ca/drugs/DB01067. [Last accessed on 10 Oct 2019].
ICH Guidelines Q2 (R1). Validation of analytical procedures: text and methodology. In: ICH Harmonized Tripartite Guidelines; 2005.